Procter & Gambl...
Health Care: Drugs
NPS Pharmaceuticals Inc (NPSP: NASDAQ)
$14.96 -0.29 | -1.90%
05/24/13 - 02:20 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -18.74M | -36.27M | -31.44M | -17.86M |
| Operating Gains/Losses | -4.00K | 646.00K | -3.75M | -6.20M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -16.01M | 18.66M | -2.27M | 2.50M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 1.32M | -3.42M | 1.86M | -17.64M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -1.25M | 84.00K | -10.45M | -3.32M |
| Other Non-Cash Items | -29.20M | -33.87M | 27.56M | 26.35M |
| Net Cash From Continuing Operations | -60.99M | -56.66M | -17.73M | -1.43M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -60.99M | -56.66M | -17.73M | -1.43M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 119.51M | 86.67M | 119.33M | 67.48M |
| Purchases of Property, Plant & Equipment | -1.19M | -3.41M | -862.00K | -248.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 5.55M |
| Purchases of Short-Term Investments | -124.81M | -111.38M | -119.20M | -67.54M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -6.49M | -28.12M | -729.00K | 5.24M |
| Issuance of Debt | 0.00 | 145.00M | 38.40M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 2.56M | 108.16M | 98.76M | 3.79M |
| Repayment of Long-Term Debt | 0.00 | -213.85M | -50.66M | -35.40M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 50.69M | -9.13M | -4.80M |
| Net Cash From Financing Activities | 2.56M | 90.00M | 77.37M | -36.41M |
| Effect of Exchange Rate Changes | -10.00K | 5.00K | -15.00K | 41.00K |
| Net Change in Cash & Cash Equivalents | -64.93M | 5.23M | 58.89M | -32.56M |
Portfolios with NPSP
- Portfolio NameUser Type
- UserMy Watch List
- UserJaq Le Blanc 09/30
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Under-$10 Moving Hig...
- Userchinahound2
- ContributorBreakout Stocks Of The Week...
- Usersalvatore Portfolio 1
- UserRocket Stocks for the week ...
Latest NPSP Headlines from TheStreet
- Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR 04.03.13 | 06:04 am
- Cramer's 'Mad Money' Recap: The Winning Formula 04.02.13 | 08:04 pm
- Mad Money Uncovered: Orphan Drug Stocks
03.20.13 | 12:03 pm - Cramer's Top Stock Picks: HTZ NPSP GLD 03.20.13 | 06:03 am
- Cramer's 'Mad Money' Recap: Be an Informed Skeptic 03.19.13 | 08:03 pm
- Tuesday Trend Continues: Morning Movers 03.19.13 | 10:03 am
- Morning Briefing: 10 Things You Should Know 03.19.13 | 05:03 am
- NPS Pharma Buys Back Worldwide Rights To Short Bowel Syndrome Drug 03.19.13 | 02:03 am
- Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma 01.18.13 | 08:01 am
- Biotech Stock Lessons From 2013 J.P. Morgan Healthcare Confab 01.14.13 | 08:01 am
Press Releases for NPSP
- NPS Pharmaceuticals And Takeda Revise Agreements And NPS Re-Gains Full Worldwide Rights To Teduglutide And Recombinant Human Parathyroid Hormone 1-84 - Business Wire 03.19.13 | 02:03 am
- NPS Pharmaceuticals To Present At Barclays Capital Global Healthcare Conference - Business Wire 03.05.13 | 08:03 am
- NPS Pharmaceuticals Observes Rare Disease Day 2013 And Celebrates 30th Anniversary Of National Organization For Rare Disorders - Business Wire 02.28.13 | 08:02 am
- NPS Pharmaceuticals Reports 2012 Financial Results And 2013 Guidance - Business Wire 02.21.13 | 04:02 pm
- NPS Pharmaceuticals To Present At RBC Capital Markets Healthcare Conference - Business Wire 02.19.13 | 04:02 pm
- NPS Pharmaceuticals To Report 2012 Financial Results - Business Wire 02.13.13 | 08:02 am
- NPS Pharmaceuticals To Present At Upcoming Conferences - Business Wire 02.05.13 | 04:02 pm
- New Peer-reviewed Publication Offers Guidance For Integrating Gattex® (Teduglutide [rDNA Origin]) For Injection Into Management Of Short Bowel Syndrome - Business Wire 01.30.13 | 08:01 am
- NPS Pharmaceuticals To Present At J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 08:01 am
- NPS Pharmaceuticals To Host Conference Call To Discuss FDA Approval Of Gattex® (teduglutide [rDNA Origin]) For Injection For The Treatment Of Adult Short Bowel Syndrome - Business Wire 01.02.13 | 08:01 am
Partner Headlines for NPSP
- Current Prime Pharma Entries In Anticipation Of Prime Time Exits - Seeking Alpha 11.06.12 | 09:11 am
- Benzinga Mid-Day Market Update - Benzinga 10.16.12 | 01:10 pm
- 3 Best Biotech Stocks For This Week (Part VI) - Seeking Alpha 10.16.12 | 08:10 am
- NPS Pharmaceuticals: Buy If There Is A Dip - Seeking Alpha 10.14.12 | 08:10 am
- UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality - Benzinga 10.04.12 | 01:10 pm
- NPS Pharma Says Gattex Meeting October 16th - Benzinga 08.21.12 | 08:08 am
- 7 High-Growth Small-Cap Stocks With Strong Buy Ratings - Seeking Alpha 07.28.12 | 09:07 am
- Amylin Pharmaceutical POPS 8.9% with 4 Stocks Hitting 52-Week Highs - Wall St. Cheat Sheet 07.03.12 | 10:07 am
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
- 6 Biotechs That Could See Huge Gains (Like Inhibitex) - Seeking Alpha 11.11.11 | 09:11 am
